113 related articles for article (PubMed ID: 9621152)
1. Acrocyanosis induced by interferon alpha(2a).
Campo-Voegeli A; Estrach T; Marti RM; Corominas N; Tuset M; Mascaró JM
Dermatology; 1998; 196(3):361-3. PubMed ID: 9621152
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha induced Raynaud's syndrome.
Kruit WH; Eggermont AM; Stoter G
Ann Oncol; 2000 Nov; 11(11):1501-2. PubMed ID: 11142493
[TBL] [Abstract][Full Text] [Related]
3. Severe Raynaud's phenomenon with chronic hepatis C disease treated with interferon.
Iorio R; Spagnuolo MI; Sepe A; Zoccali S; Alessio M; Vegnente A
Pediatr Infect Dis J; 2003 Feb; 22(2):195-7. PubMed ID: 12613457
[TBL] [Abstract][Full Text] [Related]
4. [Interferon-alpha and PUVA therapy for mycosis fungoides].
Marschalkó M; Kovács J; Somlai B; Berecz M; Hídvégi B; Hársing J; Désaknai M; Horváth A
Orv Hetil; 2001 Sep; 142(37):2021-3. PubMed ID: 11582733
[TBL] [Abstract][Full Text] [Related]
5. Interferon-induced Raynaud's syndrome.
Schapira D; Nahir AM; Hadad N
Semin Arthritis Rheum; 2002 Dec; 32(3):157-62. PubMed ID: 12528080
[TBL] [Abstract][Full Text] [Related]
6. Raynaud's phenomenon possibly induced by a compund drug of tegafur and uracil.
Seishima M; Izumi T; Kanoh H
Eur J Dermatol; 2000; 10(1):55-8. PubMed ID: 10694301
[TBL] [Abstract][Full Text] [Related]
7. Interferon α-induced lupus-like reaction in a mycosis fungoides patient: A case report.
Fatemi Naeini F; Yazdanpanah M; Mohaghegh F; Rajabi P; Tabatabaei ET
Int J Clin Pharmacol Ther; 2022 Jul; 60(7):306-310. PubMed ID: 35603683
[TBL] [Abstract][Full Text] [Related]
8. Suppression of anti-interferon alpha-2a antibody formation in patients with mycosis fungoides by exposure to long-wave UV radiation in the A range and methoxsalen ingestion.
Kuzel TM; Roenigk HH; Samuelson E; Rosen ST
J Natl Cancer Inst; 1992 Jan; 84(2):119-21. PubMed ID: 1735877
[No Abstract] [Full Text] [Related]
9. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma.
Spaccarelli N; Rook AH
Dermatol Clin; 2015 Oct; 33(4):731-45. PubMed ID: 26433845
[TBL] [Abstract][Full Text] [Related]
10. Raynaud's phenomenon associated with alpha-interferon therapy.
Arslan M; Ozyilkan E; Kayhan B; Telatar H
J Intern Med; 1994 May; 235(5):503. PubMed ID: 8182410
[No Abstract] [Full Text] [Related]
11. [Seizures during interferon alpha therapy: three cases in dermatology].
Legroux-Crespel E; Lafaye S; Mahé E; Picard-Dahan C; Crickx B; Sassolas B; Descamps V
Ann Dermatol Venereol; 2003 Feb; 130(2 Pt 1):202-4. PubMed ID: 12671585
[TBL] [Abstract][Full Text] [Related]
12. Poikilodermatous mycosis fungoides.
Farley-Loftus R; Mandal R; Latkowski JA
Dermatol Online J; 2010 Nov; 16(11):8. PubMed ID: 21163159
[TBL] [Abstract][Full Text] [Related]
13. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
14. Lamotrigine-induced lupus.
Sarzi-Puttini P; Panni B; Cazzola M; Muzzupappa S; Turiel M
Lupus; 2000; 9(7):555-7. PubMed ID: 11035425
[TBL] [Abstract][Full Text] [Related]
15. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
[TBL] [Abstract][Full Text] [Related]
16. Interferon-alpha-associated development of bullous lesions in mycosis fungoides.
Pföhler C; Ugurel S; Seiter S; Wagner A; Tilgen W; Reinhold U
Dermatology; 2000; 200(1):51-3. PubMed ID: 10681616
[TBL] [Abstract][Full Text] [Related]
17. Electrochemotherapy of Mycosis fungoides by interferon-alpha.
Peycheva E; Daskalov I; Tsoneva I
Bioelectrochemistry; 2007 May; 70(2):283-6. PubMed ID: 17150416
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
Kohn EC; Steis RG; Sausville EA; Veach SR; Stocker JL; Phelps R; Franco S; Longo DL; Bunn PA; Ihde DC
J Clin Oncol; 1990 Jan; 8(1):155-60. PubMed ID: 2295906
[TBL] [Abstract][Full Text] [Related]
19. Isolated Raynaud's phenomenon--a benign disorder.
Sheiner NM; Small P
Ann Allergy; 1987 Feb; 58(2):114-7. PubMed ID: 3492946
[TBL] [Abstract][Full Text] [Related]
20. Associations of nailfold capillary abnormalities and immunological markers in early Raynaud's phenomenon.
Schlager O; Kiener HP; Stein L; Hofkirchner J; Zehetmayer S; Ristl R; Perkmann T; Smolen JS; Koppensteiner R; Gschwandtner ME
Scand J Rheumatol; 2014; 43(3):226-33. PubMed ID: 24517537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
